Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Autism spectrum disorder (ASD) presents core symptoms of social communication deficits and repetitive behaviors, with an unmet need for effective therapies.
• Developing pharmacotherapies for ASD faces significant challenges, particularly in clinical trial conduct.
• Balovaptan, a V1a receptor antagonist, was explored for improving social communication in individuals with ASD.

Purpose of the Study:

• To describe current challenges in autism spectrum disorder (ASD) clinical trials.
• To share first-hand experiences from the balovaptan clinical development program.
• To inform the design of future ASD treatment research.

Main Methods:

• Review of three randomized clinical trials of balovaptan in individuals with ASD across a wide age range and international sites.
• Analysis of factors influencing placebo response in ASD trials.
• Examination of challenges in outcome measure selection and impact of baseline characteristics.

Main Results:

• A notable placebo response was observed across multiple outcome measures in the balovaptan trials.
• Factors predicting placebo response included higher baseline symptom severity, online participant recruitment, and less experienced trial sites.
• Challenges identified include selection of appropriate outcome measures, influence of baseline characteristics, and expectation bias.

Conclusions:

• The balovaptan program provided valuable insights into key challenges in ASD treatment research.
• These insights are crucial for improving the design of future clinical trials for ASD therapies.
• The ultimate goal is to develop effective treatments to enhance the quality of life for individuals with ASD.